In lung cancer cells, PDE5 inhibitors modulate the endocytosis probably via the increase in cGMP levels and consequently the PKG activity, enhancing the cytotoxic activity of the anti-tumoral drugs doxorubicin and cisplatin. This evidence concerns the gene PDE5A and lung cancer.